Medical imaging software firm AlgoMedica and artificial intelligence (AI) software developer InferVision have partnered to improve the performance of imaging AI software.
AlgoMedica's PixelShine will be integrated into InferVision's InferRead CT pneumonia software. The companies aim to improve the ability of the Infervision AI algorithms to analyze ultralow-dose lung CT imaging by reducing noise inherent in these studies.
The collaboration is part of a broader effort to improve the effectiveness of ultralow-dose CT in the detection of COVID-19 in patients. Both companies are partners in a consortium that is seeking 2 million euros (about $2.16 million) in funding from the European Union to establish
a standardized and quantitative procedure to enable improved, faster diagnosis of COVID-19 using AI and ultralow-dose CT.
The combined software is in the process of being installed at hospitals in several countries in Europe, including Germany and Italy.
